PCNA and neoplasm: Besides, the FXR agonist INT-767 reduces tumour growth and increases hepatoprotection in a mouse model by reducing the expressions of F4/80, IL-1β, IL-6, TNF-α, cyclin D1, proliferating cell nuclear antigen (PCNA), α-smooth muscle actin (α-Sma), CYP7A1 and collagen, and upregulation of FGF15 and SHP [145].